29.03.2012 - For the third time in a year, RNAi therapeutics specialist Silence Therapeutics has named a new CEO.
After US firm Intradigm left the merger, Thomas Christély, who is now stepping down for ”personal reasons”, took over from Philipp Haworth. He will be replaced by Dr Tony Sedgwick. He joined Silence in September 2011 to lead a new business development team. He has extensive experience from European life science companies including more than fifteen years at Roche. Prior to joining Silence, Sedgwick was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS. He was also previously CEO of Daniolabs Ltd. and Cambridge Biotechnology Ltd.